ANEW MEDICAL, INC. Achieves Debt-Free Status, Boosts Financial Flexibility
26 août 2024 05h00 HE | ANEW MEDICAL, INC.
ANEW MEDICAL, INC. Achieves Debt-Free Status, Boosts Financial Flexibility
American Institutes
American Institutes for Research To Help Implement Federal Program Aimed at Increasing Access to Transformative Cell and Gene Therapy Treatments
21 août 2024 12h00 HE | American Institutes for Research
Arlington, Va., Aug. 21, 2024 (GLOBE NEWSWIRE) -- The American Institutes for Research (AIR) has been awarded a federal contract to help implement and monitor a new program that seeks to make...
Gene Therapy Market
Gene Therapy Market Size, Share & Trends Analysis Report 2024-2030, By Indication, By Vector Type, By Route Of Administration, By Region and Segment Forecasts
20 août 2024 06h28 HE | Research and Markets
Dublin, Aug. 20, 2024 (GLOBE NEWSWIRE) -- The "Gene Therapy Market Size, Share & Trends Analysis Report By Indication (Acute Lymphoblastic Leukemia, Large B-cell Lymphoma), By Vector Type...
Logo-uniQure-MS-Word_Orange.jpg
uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease
15 août 2024 07h05 HE | uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, Aug. 15, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
ANEW MEDICAL, INC. Strengthens Intellectual Property Protection with U.S. Patent Issuance for Its Secreted RNA Splice Variant of the Human Klotho Gene Used for the Treatment of Neurodegenerative and Age-Related Diseases
15 août 2024 05h00 HE | ANEW MEDICAL, INC.
NEW YORK, Aug. 15, 2024 (GLOBE NEWSWIRE) -- ANEW MEDICAL, INC. (“ANEW” or “the Company”) (NASDAQ: WENA) a U.S. -based biotechnology company focused on developing cell and gene-based treatments for...
Fractyl-Logo.png
Fractyl Health Reports Second Quarter 2024 Financial Results and Provides Business Updates
14 août 2024 16h05 HE | Fractyl Health, Inc.
Fractyl Health Reports Second Quarter 2024 Financial Results and Provides Business Updates
Dr. Yen-Michael Hsu
Gift of Life Marrow Registry Names Dr. Yen-Michael Hsu as Co-Chief Medical Officer
13 août 2024 11h47 HE | Gift of Life Marrow Registry
BOCA RATON, Fla., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Gift of Life Marrow Registry today announced the appointment of Yen-Michael Hsu, M.D., Ph.D., MBA, CABP as Co-Chief Medical Officer. Dr. Hsu's...
ocugen_4C_LOGO (002).png
Ocugen Provides Business Update with Second Quarter 2024 Financial Results
08 août 2024 06h45 HE | Ocugen
Conference Call and Webcast Today at 8:30 a.m. ET Actively dosing patients in OCU400 Phase 3 liMeliGhT clinical trialOCU410 preliminary safety and efficacy data expected later this year Expanded...
ocugen_4C_LOGO (002).png
Ocugen, Inc. Announces FDA Approval of Expanded Access Program for Patients with Retinitis Pigmentosa
05 août 2024 06h30 HE | Ocugen
MALVERN, Pa., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...
ocugen_4C_LOGO (002).png
Ocugen, Inc. Announces Closing of $35 Million Public Offering of Common Stock
02 août 2024 15h22 HE | Ocugen
MALVERN, Pa., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and...